Domenico Bonaduce

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/524230/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors. Current Oncology Reports, 2021, 23, 13.	1.8	38
2	A nutraceutical combination reduces left ventricular mass in subjects with metabolic syndrome and left ventricular hypertrophy: A multicenter, randomized, double-blind, placebo-controlled trial. Clinical Nutrition, 2020, 39, 1379-1384.	2.3	13
3	Type 2 myocardial infarction: is it a geriatric syndrome?. Aging Clinical and Experimental Research, 2020, 32, 759-768.	1.4	7
4	Validation of "(fr)AGILEâ€: a quick tool to identify multidimensional frailty in the elderly. BMC Geriatrics, 2020, 20, 375.	1.1	14
5	Effect of Sacubitril-Valsartan in reducing depression in patients with advanced heart failure. Journal of Affective Disorders, 2020, 272, 132-137.	2.0	13
6	Commentary on "Functional Improvement After Outpatient Cardiac Rehabilitation in Acute Coronary Syndrome Patients is not Related to Improvement in Left Ventricular Ejection Fraction― High Blood Pressure and Cardiovascular Prevention, 2020, 27, 179-181.	1.0	0
7	Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty. ESC Heart Failure, 2020, 7, 757-762.	1.4	28
8	Sarcopenia and Heart Failure. Nutrients, 2020, 12, 211.	1.7	124
9	Bmi1 inhibitor PTC-209 promotes Chemically-induced Direct Cardiac Reprogramming of cardiac fibroblasts into cardiomyocytes. Scientific Reports, 2020, 10, 7129.	1.6	28
10	Pharmacological inhibition of <scp>GRK2</scp> improves cardiac metabolism and function in experimental heart failure. ESC Heart Failure, 2020, 7, 1571-1584.	1.4	21
11	Physical vs. multidimensional frailty in older adults with and without heart failure. ESC Heart Failure, 2020, 7, 1371-1380.	1.4	16
12	Protective effect of physical activity on mortality in older adults with advanced chronic heart failure: A prospective observational study. European Journal of Preventive Cardiology, 2019, 26, 481-488.	0.8	31
13	What Is the Cardiac Impact of Chemotherapy and Subsequent Radiotherapy in Lymphoma Patients?. Antioxidants and Redox Signaling, 2019, 31, 1166-1174.	2.5	21
14	Inflammatory, Serological and Vascular Determinants of Cardiovascular Disease in Systemic Lupus Erythematosus Patients. International Journal of Molecular Sciences, 2019, 20, 2154.	1.8	26
15	The novel butyrate derivative phenylalanineâ€butyramide protects from doxorubicinâ€induced cardiotoxicity. European Journal of Heart Failure, 2019, 21, 519-528.	2.9	80
16	Multidimensional frailty evaluation in elderly outpatients with chronic heart failure: A prospective study. European Journal of Preventive Cardiology, 2019, 26, 1115-1117.	0.8	17
17	Permanent atrial fibrillation and pulmonary embolism in elderly patients without deep vein thrombosis: is there a relationship?. Aging Clinical and Experimental Research, 2019, 31, 1121-1128.	1.4	8
18	Physical Activity Scale for the Elderly (PASE) Score Is Related to Sarcopenia in Noninstitutionalized Older Adults. Journal of Geriatric Physical Therapy, 2019, 42, 130-135.	0.6	30

#	Article	IF	CITATIONS
19	New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension. Current Medicinal Chemistry, 2019, 26, 2844-2864.	1.2	23
20	Acute care hospital at different levels of intensity: the role of Geriatrician. Aging Clinical and Experimental Research, 2018, 30, 703-712.	1.4	3
21	Risk of Malnutrition Evaluated by Mini Nutritional Assessment and Sarcopenia in Noninstitutionalized Elderly People. Nutrition in Clinical Practice, 2018, 33, 879-886.	1.1	37
22	Thromboembolic and bleeding risk management in elderly patients: a case report. Aging Clinical and Experimental Research, 2018, 30, 1011-1013.	1.4	0
23	The reverse metabolic syndrome in the elderly: Is it a "catabolic―syndrome?. Aging Clinical and Experimental Research, 2018, 30, 547-554.	1.4	13
24	Pharmacovigilating cardiotoxicity of immune checkpoint inhibitors. Lancet Oncology, The, 2018, 19, 1545-1546.	5.1	16
25	A common polymorphism in the SCN5A gene is associated with dilated cardiomyopathy. Journal of Cardiovascular Medicine, 2018, 19, 344-350.	0.6	21
26	Orthostatic Hypotension in the Elderly: A Marker of Clinical Frailty?. Journal of the American Medical Directors Association, 2018, 19, 779-785.	1.2	32
27	Oxidative stress, aging, and diseases. Clinical Interventions in Aging, 2018, Volume 13, 757-772.	1.3	2,366
28	Sarcopenia: assessment of disease burden and strategies to improve outcomes. Clinical Interventions in Aging, 2018, Volume 13, 913-927.	1.3	198
29	Impact of SPRINT results on hypertension guidelines: implications for "frail―elderly patients. Journal of Human Hypertension, 2018, 32, 633-638.	1.0	32
30	Depression and chronic heart failure in the elderly: an intriguing relationship. Journal of Geriatric Cardiology, 2018, 15, 451-459.	0.2	30
31	Chronic obstructive pulmonary disease and long-term mortality in elderly subjects with chronic heart failure. Aging Clinical and Experimental Research, 2017, 29, 1157-1164.	1.4	20
32	The Italian version of the "frailty index―based on deficits in health: a validation study. Aging Clinical and Experimental Research, 2017, 29, 913-926.	1.4	50
33	Cardiotoxicity of immune checkpoint inhibitors. ESMO Open, 2017, 2, e000247.	2.0	186
34	Syncope and Epilepsy coexist in â€~possible' and â€~drug-resistant' epilepsy (Overlap between Epilepsy a	and) Tj ET(
35	Nanotechnology-Based Cardiac Targeting and Direct Cardiac Reprogramming: The Betrothed. Stem	1.2	22

Growth Hormone Deficiency Is Associated with Worse Cardiac Function, Physical Performance, and
Outcome in Chronic Heart Failure: Insights from the T.O.S.CA. GHD Study. PLoS ONE, 2017, 12, e0170058.

#	Article	IF	CITATIONS
37	The Influence of Fiber on Gut Microbiota: Butyrate as Molecular Player Involved in theÂBeneficial Interplay BetweenÂDietary Fiber and Cardiovascular Health. , 2017, , 61-71.		4
38	Long-term prognostic value of stress myocardial perfusion imaging and coronary computed tomography angiography: A meta-analysis. Journal of Nuclear Cardiology, 2016, 23, 185-197.	1.4	20
39	Tinetti mobility test is related to muscle mass and strength in non-institutionalized elderly people. Age, 2016, 38, 525-533.	3.0	29
40	Biomarkers in sarcopenia: A multifactorial approach. Experimental Gerontology, 2016, 85, 1-8.	1.2	145
41	Prognostic role of lactate on mortality in younger and older patients with cardio-respiratory failure admitted to an acute intensive care unit. Aging Clinical and Experimental Research, 2016, 28, 407-412.	1.4	5
42	Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs. BioMed Research International, 2015, 2015, 1-14.	0.9	34
43	Quantitative Assessment of Myocardial Blood Flow with SPECT. Progress in Cardiovascular Diseases, 2015, 57, 607-614.	1.6	28
44	Butyryl-cholinesterase is related to muscle mass and strength. A new biomarker to identify elderly subjects at risk of sarcopenia. Biomarkers in Medicine, 2015, 9, 669-678.	0.6	28
45	Mitral peak early diastolic filling velocity to deceleration time ratio as a predictor of prognosis in patients with chronic heart failure and preserved or reduced ejection fraction. Journal of Geriatric Cardiology, 2015, 12, 346-52.	0.2	4
46	Arterial Wave Reflections and Ventricular-Vascular Interaction in Patients With Left Ventricular Systolic Dysfunction. International Heart Journal, 2014, 55, 526-532.	0.5	15
47	Long-term mortality in frail elderly subjects with osteoarthritis. Rheumatology, 2014, 53, 293-299.	0.9	32
48	β-adrenergic receptor responsiveness in aging heart and clinical implications. Frontiers in Physiology, 2014, 4, 396.	1.3	115
49	Atenolol use is associated with longâ€ŧerm mortality in communityâ€dwelling older adults with hypertension. Geriatrics and Gerontology International, 2014, 14, 153-158.	0.7	5
50	Cognitive impairment and cardiovascular diseases in the elderly. A heart–brain continuum hypothesis. Ageing Research Reviews, 2014, 18, 41-52.	5.0	149
51	Phase angle as bioelectrical marker to identify elderly patients at risk of sarcopenia. Experimental Gerontology, 2014, 58, 43-46.	1.2	125
52	Autonomic Dysfunction in Alzheimer's Disease: Tools for Assessment and Review of the Literature. Journal of Alzheimer's Disease, 2014, 42, 369-377.	1.2	94
53	Hemodialysis does not affect ventricular–arterial coupling beyond the reduction of blood pressure and preload. International Journal of Cardiology, 2013, 168, 1553-1554.	0.8	3
54	Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. International Journal of Cardiology, 2013, 168, 1545-1547.	0.8	50

#	Article	IF	CITATIONS
55	Neuro-hormonal effects of physical activity in the elderly. Frontiers in Physiology, 2013, 4, 378.	1.3	10
56	Effects of exercise training on cardiovascular adrenergic system. Frontiers in Physiology, 2013, 4, 348.	1.3	57
57	Prognostic value of coronary artery calcium score and coronary CT angiography in patients with intermediate risk of coronary artery disease. International Journal of Cardiovascular Imaging, 2012, 28, 1547-1556.	0.7	43
58	Review and Metaanalysis of the Frequency of Familial Dilated Cardiomyopathy. American Journal of Cardiology, 2011, 108, 1171-1176.	0.7	109
59	Systemic capillary leak syndrome or Clarkson's disease: a case report. Internal and Emergency Medicine, 2009, 4, 357-358.	1.0	6
60	Prognostic value of reduced kidney function and anemia in patients with chronic heart failure. Journal of Cardiovascular Medicine, 2007, 8, 909-916.	0.6	7
61	NT-proBNP, IGF-I and survival in patients with chronic heart failure. Growth Hormone and IGF Research, 2007, 17, 288-296.	0.5	51
62	Effects of volume loading on strain rate and tissue Doppler velocity imaging in patients with idiopathic dilated cardiomyopathy. Journal of Cardiovascular Medicine, 2006, 7, 852-858.	0.6	18
63	Influence of risk factors on coronary flow reserve in patients with 1-vessel coronary artery disease. Journal of Nuclear Medicine, 2005, 46, 1438-43.	2.8	10
64	Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12Âmonths of treatment with the depot long-acting somatostatin analogue octreotide. Clinical Endocrinology, 2003, 58, 169-176.	1.2	99
65	High Prevalence of Cardiac Valve Disease in Acromegaly: An Observational, Analytical, Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3196-3201.	1.8	119
66	Left Ventricular Diastolic Function and Cardiac Performance during Exercise in Patients with Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4105-4109.	1.8	12
67	Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 1689-1694.	3.3	77
68	Cardiovascular Consequences of Early-Onset Growth Hormone Excess. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3097-3104.	1.8	82
69	Combined effect of the force-frequency and length-tension mechanisms on left ventricular function in patients with dilated cardiomyopathy. European Journal of Heart Failure, 2002, 4, 727-735.	2.9	7
70	Losartan treatment and left ventricular filling during volume loading in patients with dilated cardiomyopathy. American Heart Journal, 2002, 143, 433-440.	1.2	8
71	Efficacy of Thrombolysis in Younger and Older Adult Patients Suffering Their First Acute Qâ€Wave Myocardial Infarction. Journal of the American Geriatrics Society, 2002, 50, 343-348	1.3	8
72	The Cardiovascular Risk of Adult GH Deficiency (GHD) Improved after GH Replacement and Worsened in Untreated GHD: A 12-Month Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1088-1093.	1.8	33

#	Article	IF	CITATIONS
73	A multicenter, randomized double-blind study of valsartan/hydrochlorothiazide combination versus amlodipine in patients with mild to moderate hypertension. Journal of Hypertension, 2001, 19, 1691-1696.	0.3	19
74	Cardiovascular haemodynamics and cardiac autonomic control in patients with subclinical and overt hyperthyroidism. European Journal of Endocrinology, 2001, 145, 691-696.	1.9	93
75	Improved Cardiovascular Risk Factors and Cardiac Performance after 12 Months of Growth Hormone (CH) Replacement in Young Adult Patients with CH Deficiency1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1874-1881.	1.8	115
76	Circulating levels of cytokines and their site of production in patients with mild to severe chronic heart failure. American Heart Journal, 2000, 140, 12A-18A.	1.2	56
77	Wavelet transform analysis of heart rate variability during dipyridamoleâ€induced myocardial ischemia: Relation to angiographic severity and echocardiographic dyssynergy. Clinical Cardiology, 1999, 22, 201-206.	0.7	8
78	Independent and incremental prognostic value of heart rate variability in patients with chronic heart failure. American Heart Journal, 1999, 138, 273-284.	1.2	85
79	Comparison of verapamil versus felodipine on heart rate variability in hypertensive patients. Journal of Hypertension, 1999, 17, 707-713.	0.3	11
80	Combined assessment of left ventricular function and rest-redistribution regional myocardial thallium-201 activity for prognostic evaluation of patients with chronic coronary artery disease and left ventricular dysfunction. Journal of Nuclear Cardiology, 1998, 5, 378-386.	1.4	25
81	Intensive training and cardiac autonomic control in high level athletes. Medicine and Science in Sports and Exercise, 1998, 30, 691-696.	0.2	72
82	Heart rate variability in patients with hypertrophic cardiomyopathy: Association with clinical and echocardiographic features. American Heart Journal, 1997, 134, 165-172.	1.2	26
83	Comparison of Verapamil Versus Felodipine on Heart Rate Variability After Acute Myocardial Infarction. American Journal of Cardiology, 1997, 79, 564-569.	0.7	20
84	Heart rate variability as a measure of autonomic nervous system function in anorexia nervosa. Clinical Cardiology, 1997, 20, 219-224.	0.7	88
85	Successful coronary revascularization improves prognosis in patients with previous myocardial infarction and evidence of viable myocardium at thallium-201 imaging. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 25, 60-68.	3.3	54
86	Prognostic value of coronary angiography in patients with chronic ischemic left ventricular dysfunction and evidence of viable myocardium on thallium reinjection imaging. Journal of Nuclear Cardiology, 1997, 4, 387-395.	1.4	7
87	Converting enzyme inhibition, heart rate variability, and myocardial infarction. American Journal of Cardiology, 1996, 78, 609.	0.7	1
88	Effect of 1 Year of Lisinopril Treatment on Cardiac Autonomic Control in Hypertensive Patients With Left Ventricular Hypertrophy. Hypertension, 1996, 27, 330-338.	1.3	19
89	Influence of left ventricular hypertrophy on heart period variability in patients with essential hypertension, 1995, 13, 1299-1306.	0.3	20
90	Assessment of cardiac autonomic control by heart period variability in patients with early-onset familial obesity. European Journal of Clinical Investigation, 1995, 25, 826-832.	1.7	49

#	Article	IF	CITATIONS
91	Power spectral analysis of heart period variability in hypertensive patients with left ventricular hypertrophy. American Journal of Hypertension, 1995, 8, 1206-1213.	1.0	28
92	Prognostic value of myocardial hypoperfusion indexes in patients with suspected or known coronary artery disease. Journal of Nuclear Cardiology, 1994, 1, 325-337.	1.4	5
93	Continuous electrocardiographic monitoring for more than one hour does not improve the prognostic value of ventricular arrhythmias in survivors of first acute myocardial infarction. American Journal of Cardiology, 1994, 73, 139-142.	0.7	6
94	Influence of reversible segmental left ventricular dysfunction on heart period variability in patients with one-vessel coronary aetery disease. Journal of the American College of Cardiology, 1994, 24, 399-405.	1.2	21
95	Left ventricular remodelling in the year after myocardial infarction. Coronary Artery Disease, 1994, 5, 155-162.	0.3	16
96	Effects of converting enzyme inhibition on heart period variability in patients with acute myocardial infarction Circulation, 1994, 90, 108-113.	1.6	126
97	Effects of acetylstrophanthidin on baroreflex sensitivity in patients with acute myocardial infarction. International Journal of Cardiology, 1993, 41, 3-11.	0.8	1
98	Incremental prognostic value of thallium imaging and coronary angiography in patients with a symptom-limited ECG stress test. Coronary Artery Disease, 1993, 4, 637-644.	0.3	2
99	Effects of sustained training on left ventricular structure and function in top level rowers. European Heart Journal, 1993, 14, 898-903.	1.0	19
100	Effects of converting enzyme inhibition on baroreflex sensitivity in patients with myocardial infarction. Journal of the American College of Cardiology, 1992, 20, 587-593.	1.2	21
101	Effects of captopril treatment on left ventricular remodeling and function after anterior myocardial infarction: Comparison with digitalis. Journal of the American College of Cardiology, 1992, 19, 858-863.	1.2	50
102	Characterization and prognostic significance of silent myocardial ischemia on predischarge electrocardiographic monitoring in unselected patients with myocardial infarction. American Journal of Cardiology, 1992, 69, 579-583.	0.7	36
103	Doppler Echocardiographie Evaluation of Three Models of Prosthetic Valves in the Aortic Position. American Journal of Noninvasive Cardiology, 1991, 5, 98-102.	0.1	0
104	Prevalence and prognostic significance of silent myocardial ischaemia detected by exercise test and continuous ECG monitoring after acute myocardial infarction. European Heart Journal, 1991, 12, 186-193.	1.0	44
105	Usefulness of late coronary thrombolysis (recombinant tissue-type plasminogen activator) in preserving left ventricular function in acute myocardial infarction. American Journal of Cardiology, 1990, 66, 1281-1286.	0.7	14
106	Phase analysis of radionuclide angiography in acute myocardial infarction. European Journal of Nuclear Medicine and Molecular Imaging, 1990, 16, 161-165.	2.2	3
107	Effects of late administration of tissue-type plasminogen activator on left ventricular remodeling and function after myocardial infarction. Journal of the American College of Cardiology, 1990, 16, 1561-1568.	1.2	43
108	Influence of Normalization Techniques upon Two-Dimensional Doppler-Derived Peak Filling Rate: Comparison with Radionuclide Angiography. American Journal of Noninvasive Cardiology, 1989, 3, 74-79	0.1	0

#	Article	IF	CITATIONS
109	Myocardial hypertrophy and left ventricular diastolic function in hypertensive patients: an echo Doppler evaluation. European Heart Journal, 1989, 10, 611-621.	1.0	28
110	Efficacy of magnesium sulfate in the treatment of torsade de pointes. American Heart Journal, 1986, 112, 847-849.	1.2	82
111	Evaluation of the Efficacy of Slow-Release Nifedipine in Systemic Hypertension by Ambulatory Intraarterial Blood Pressure Monitoring. Journal of Cardiovascular Pharmacology, 1985, 7, 145-151.	0.8	24
112	Orthostatic hypotension due to autonomic dysfunction - different therapeutic effects of propranolol. International Journal of Cardiology, 1983, 4, 455-462.	0.8	5
113	Hemodynamic study of nifedipine administration in hypertensive patients. American Heart Journal, 1983, 105, 865-867.	1.2	16
114	Comparison of the antihypertensive activities of xipamide and chlorthalidone: a double-blind, randomized, crossover trial. Current Medical Research and Opinion, 1981, 7, 247-252.	0.9	10